Naturally nonanemic dialysis patients: Who are they?

Yilmaz M., Kircelli F., Artan A. S., OTO Ö. A., AŞCI G., Gunestepe K., ...Daha Fazla

HEMODIALYSIS INTERNATIONAL, cilt.20, sa.4, ss.522-529, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1111/hdi.12425
  • Dergi Adı: HEMODIALYSIS INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.522-529
  • Anahtar Kelimeler: Hemodialysis, anemia, erythropoiesis stimulating agent, treatment, survival, CHRONIC KIDNEY-DISEASE, ERYTHROPOIESIS-STIMULATING AGENTS, INCIDENT HEMODIALYSIS-PATIENTS, HEMOGLOBIN VARIABILITY, EPOETIN-ALPHA, RENAL-DISEASE, MORTALITY, ANEMIA, HEMATOCRIT, SURVIVAL
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Introduction Not only anemia, but also erythropoiesis stimulating agent (ESA)s for treating anemia may adversely affect prognosis of chronic hemodialysis patients. Various features of naturally (with no ESA usage) nonanemic patients may be useful for defining several factors in the pathogenesis of anemia. Methods Data, retrieved from the European Clinical Database (EuCliD)-Turkey on naturally nonanemic prevalent chronic hemodialysis patients (n: 201) were compared with their anemic (those who required ESA treatment) counterparts (n: 3948). Findings Mean hemoglobin values were 13.5 +/- 0.8 and 11.5 +/- 0.9 g/dL in nonanemic and anemic patients, respectively (P < 0.001). Nonanemia status was associated with younger age, male gender, longer dialysis vintage, nondiabetic status, more frequent hepatitis-C virus seropositivity and more frequent arteriovenous fistula usage. Serum ferritin and CRP levels and urea reduction ratio were higher in ESA-requiring patients. One (99%) and two (95.3%) years survival rates of the "naturally nonanemic" patients were superior as compared to anemics (91.0% and 82.6%, respectively), (P < 0.001). Discussion "Naturally nonanemic" status is associated with better survival in prevalent chronic hemodialysis patients; underlying mechanisms in this favorable outcome should be investigated by randomized controlled trials including large number of patients.